Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

PHIO US Equity

Phio Pharmaceuticals Corp.Health Care · Pharmaceutical Preparations · CIK 1533040 · FY ends Dec 31
$1.15
+0.10 (+9.52%)
USD · as of 2026-08-19 · marketstack

PHIO · 10-K · period ended 2024-12-31

← all PHIO documents
filed 2025-03-31 · EDGAR original ↗

Our rendering of the filing — original pagination and typography are not reproduced, and tables are reduced to their short label cells (the figures live on FA). Nothing is summarized: every line below is the filing's own text.

blocks 4921,091 of 2,692249k characters rendered

ITEM 1A. RISK FACTORS

Risks Relating to Our Business and Industry

We are dependent on the success of our INTASYL

technology, and our product candidates based on this platform, which is unproven and may never lead to approved and marketable products.

Our efforts have been focused on the development of

product candidates based on our INTASYL technology. We have invested, and we expect to continue to invest, significant financial resources

and efforts developing our product candidates. Our ability to eventually generate revenue is highly dependent on the successful development,

regulatory approval and commercialization of our INTASYL product candidates by us or by collaborative partners, which may not occur for

the foreseeable future, if ever, and is highly uncertain and depends on a number of factors, many of which are beyond our control. Therefore,

it is difficult to accurately predict challenges we may face with our product candidates as they move through the discovery, preclinical

and clinical development stages. We will spend large amounts of money developing our INTASYL technology and may never succeed in obtaining

regulatory approval. In addition, our research methodology may be unsuccessful in identifying product candidates and results from preclinical

studies and clinical trials may not predict the results that will be obtained in later phase trials of our product candidates or our product

candidates may interact with patients in unforeseen or harmful ways that may make it impractical or impossible to manufacture, receive

regulatory approval or commercialize. If we are not successful in bringing an INTASYL product candidate to market, it will negatively

impact our business and financial condition and we may not be able to identify and successfully implement an alternative product development

strategy.

Our product candidates

are in an early stage of development and we may fail, experience significant delays, never advance clinical development or not be successful

in our efforts to identify or discover additional product candidates, which may materially and adversely impact our business.

Our success depends heavily on the successful development

of our product candidates, which may never occur. Our product candidates, which are in early stages of development, could be delayed,

not advance into the clinic, or unexpectedly fail at any stage of development. Our ability to identify, develop and commercialize product

candidates is dependent on extensive preclinical and other non-clinical tests in order to support an IND in the United States, or the

equivalent with regulatory authorities in other jurisdictions, if applicable. These research programs to identify new product candidates

require substantial financial and human resources, are difficult to design and can take many years to complete.

We cannot be certain of the outcome of our research

studies and clinical trials and the results from these studies and clinical trials may not predict the results that will be obtained in

later stages of development and we may focus our efforts and resources on product candidates that may prove to be unsuccessful. There

is no assurance that we will be able to successfully develop our product candidates, and we may forego opportunities with certain product

candidates or for indications that later prove to have greater commercial potential. If we are not able to successfully develop our product

candidates, we may be forced to abandon or delay our development efforts, which may materially and adversely affect our business, financial

condition, and results of operations.

Further, the FDA may not accept the results of our

preclinical studies or clinical trials and may require us to complete additional studies or impose stricter approval conditions than we

expect, which could impact the value of a particular program, the approvability or commercialization of the particular product candidate

or product and our Company in general. Because of these factors, it is difficult to predict the time and cost of the development of our

product candidates. Any delay or failure in obtaining required approvals may prevent us from completing our preclinical studies or clinical

trials and could have a material adverse effect on our ability to initiate or commercialize drug or biologic candidate on a timely basis,

or at all. Additionally, preclinical studies and clinical trials are lengthy and expensive and if our cash resources become limited, we

may not be able to commence, continue or complete such preclinical studies or clinical trials.

If we experience delays or difficulties in identifying

and enrolling patients in clinical trials, it may lead to delays in generating clinical data and the receipt of necessary regulatory approvals.

Clinical trials of a new drug or biologic candidate

require the enrollment of a sufficient number of patients, including patients who are suffering from the disease or condition the drug

or biologic candidate is intended to treat and who meet other eligibility criteria. Rates of patient enrollment are affected by many factors,

and delays in patient enrollment can result in increased costs and longer development times, which could materially and adversely impact

our business and financial condition. We may experience slower than expected patient enrollment in our current or future clinical trials.

In addition, clinical trials for drug or biologic candidates that treat the same indications as our product candidates may result in patients

who would otherwise be eligible for our clinical trials instead enrolling in clinical trials for other drug or biologic candidates.

Topline data may not accurately reflect or may

materially differ from the complete results of a clinical trial.

From time to time, we may publicly disclose topline

or interim data from our clinical trials based on a preliminary analysis of then-available data, of which the results, related findings

and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. We also make

assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity

to fully and carefully evaluate all data. Preliminary observations made in early stages of clinical trials are not necessarily indicative

of results that will be obtained when full data sets are analyzed or in subsequent clinical trials. As a result, topline data may differ

from future results from the same studies or different conclusions may qualify such results once additional data has been received and

evaluated. Topline or interim data also remain subject to audit and verification procedures that may result in the final data being materially

different from the preliminary data that we publicly disclose and should be viewed with caution until the complete data is available.

If the topline data we report differs from future analysis of results, or if others, including regulatory authorities, disagree with the

conclusions reached, our business, financial condition, and results of operations could be materially and adversely affected.

We rely upon third-parties to conduct our clinical

trials and other studies for our product candidates, and if they do not successfully fulfill their obligations, the development of our

product candidates may be materially impacted.

We rely upon third-party CROs, medical institutions,

collaborators, clinical investigators, consultants and other third-parties to support and conduct our clinical trials and we rely on these

third-party CROs for the execution of certain of our preclinical studies and expect to continue to do so. Because we rely on these third-parties,

we cannot necessarily control the timing, quality of work or amount of resources that our contract partners will devote to these activities.

We, our collaborators, and our CROs are responsible for ensuring that our clinical trials are conducted in accordance with applicable

regulations and protocols. If we, our collaborators, or our CROs fail to comply with these applicable regulations, the FDA may not accept

these data and may require us to complete additional preclinical studies and clinical trials, which could result in significant additional

costs and delays to us.

As we only control certain aspects of their activities,

we cannot guarantee that these partners will fulfill their obligations to us under these arrangements. If these third-parties do not successfully

carry out their responsibilities, as well as within a timely fashion, our clinical trials and preclinical studies may be delayed, unsuccessful

or otherwise adversely affected. If we have to enter into alternative arrangements it may delay or adversely affect the development of

our product candidates and our business operations. This could be difficult, costly or impossible, and our preclinical studies or clinical

trials may need to be extended, delayed, terminated or repeated, and we may not be able to obtain regulatory approval in a timely fashion,

or at all, for the applicable drug or biologic candidate, or to commercialize such drug or biologic candidate being tested in such studies

or trials.

Changes in U.S. and international trade policies

may adversely impact our business and operating results.

From time to time, proposals are made to significantly

change existing trade agreements and relationships between the U.S. and other countries. In recent years, the U.S. government has implemented

substantial changes to U.S. trade policies, including import restrictions, increased import tariffs and changes in U.S. participation

in multilateral trade agreements. Because some of our vendors, manufactures and suppliers are located in other foreign countries, we are

exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies, laws, rules and regulations

of the United States or foreign governments, as well as political unrest or unstable economic conditions in foreign countries. The U.S.

government has indicated its intent to adopt a new approach to trade policy and in some cases to renegotiate, or potentially terminate,

certain existing bilateral or multi-lateral trade agreements. For example, on February 1, 2025, President Donald Trump signed executive

orders imposing a 25% tariff on certain imports from Mexico and Canada, and a 10% tariff on certain imports from China, which were to

take effect on February 4, 2025. President Donald Trump also announced a plan for reciprocal tariffs which are to take effect on April

2. Our supply may in the future be subject to these tariffs, which could increase our manufacturing costs and could make our products,

if successfully developed and approved, less competitive than those of our competitors whose inputs are not subject to these tariffs.

We may otherwise experience supply disruptions or delays, and our suppliers may not continue to provide us with clinical supply in our

required quantities, to our required specifications and quality levels or at attractive prices. Such disruption could have adverse effects

on the development of our product candidates and our business operations.

A number of different factors could prevent us

from advancing into clinical development, obtaining regulatory approval, and ultimately commercializing our product candidates on a timely

basis, or at all.

Before obtaining regulatory approval for the sale of

any drug or biologic candidate, we must conduct extensive preclinical tests and successful clinical trials to demonstrate the safety and

efficacy of our product candidates in humans. Before human clinical trials may commence, we must submit to the FDA an IND. An IND involves

the completion of preclinical studies and the submission of the results, together with proposed clinical protocols, manufacturing information,

analytical data and other data in the IND submission. The FDA may require us to complete additional preclinical studies or disagree with

our clinical trial study design. Also, animal models may not exist for some of the disease areas we choose to develop our product candidates

for. As a result, our clinical trials may be delayed or we may be required to incur more expense than we anticipated.

Clinical trials require the review and oversight of

IRBs, which approve and continually review clinical investigations and protect the rights and welfare of patients. Before our clinical

trials can begin, we must also submit to the FDA a clinical protocol accompanied by the approval of the IRB at the institution(s) participating

in the clinical trial. An inability or delay in obtaining IRB approval could prevent or delay the initiation and completion of our clinical

trials, and the FDA may decide not to consider any data or information derived from a clinical investigation not subject to initial and

continuing IRB review and approval.

Preclinical studies and clinical trials are lengthy

and expensive, and their outcome is highly uncertain. Historical failure rates are high due to a number of factors, such as safety and

efficacy of drug or biologic candidates. We, our collaborators, the FDA, or an IRB may suspend clinical trials of a drug or biologic candidate

at any time for various reasons, including if we or they believe the patients participating in such trials are being exposed to unacceptable

health risks. Among other reasons, adverse side effects of a drug or biologic candidate on patients in a clinical trial could result in

the FDA suspending or terminating the clinical trial and refusing to approve a particular drug or biologic candidate for any or all indications

of use.

An additional number of factors could affect the timing,

cost or outcome of our drug development efforts, including the following:

· Difficulty in securing centers to conduct clinical trials;

· The cost of our clinical trials being greater than we anticipate;

· Adverse results obtained by other companies developing similar drugs.

A failure of any preclinical study or clinical trial

can occur at any stage of testing. Any delay or failure in obtaining required approvals may prevent us from completing our preclinical

studies or clinical trials and could have a material adverse effect on our ability to initiate or commercialize any drug or biologic candidate

on a timely basis, or at all. Additionally, preclinical studies and clinical trials are lengthy and expensive and if our cash resources

become limited we may not be able to commence, continue or complete our clinical trials, which could have a material impact on our business,

financial condition, and results of operations.

Disruptions at the FDA, including due to a reduction

in the FDA’s workforce and/or inadequate funding for the FDA, could prevent the FDA from performing normal functions on which our

business relies, which could negatively impact our business.

The ability of the FDA to review and approve new products

or review other regulatory submissions can be affected by a variety of factors, including statutory, regulatory and policy changes, inadequate

government budget and funding levels, a reduction in the FDA’s workforce and its ability to hire and retain key personnel. Disruptions

at the FDA and other agencies may also increase the time to meet with and receive agency feedback, review and/or approve our submissions,

conduct inspections, issue regulatory guidance, or take other actions that facilitate the development, approval and marketing of regulated

products, which would adversely affect our business. In addition, government proposals to reduce or eliminate budgetary deficits may include

reduced allocations to the FDA and other related government agencies. For example, the current President Trump administration (the “Trump

Administration”) recently established the Department of Government Efficiency, which implemented a federal government hiring

freeze and announced certain additional efforts to reduce federal government employee headcount and the size of the federal government.

It is unclear how these executive actions or other potential actions by the Trump Administration or other parts of the federal government

will impact the FDA or other regulatory authorities that oversee our business. These budgetary pressures may reduce the FDA’s ability

to perform its responsibilities. If a significant reduction in the FDA’s workforce occurs, the FDA’s budget is significantly

reduced or a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our

regulatory submissions or take other actions critical to the development or marketing of our products, if approved, which could have a

material adverse effect on our business.

We are subject to significant competition and

may not be able to compete successfully.

The biotechnology and pharmaceutical industries are

intensely competitive, contain a high degree of risk and there are many other companies actively engaged in the discovery, development

and commercialization of products that may compete with our product candidates. Many of our competitors have substantially greater experience

and greater research and development capabilities, staffing, financial, manufacturing, marketing, technical and other resources than us,

and we may not be able to successfully compete with them. These companies include large and small pharmaceutical and biotechnology companies,

academic institutions, government agencies and other private and public research organizations.

In addition, even if we are successful in developing

our product candidates, in order to compete successfully we may need to be first to market or to demonstrate that our products are superior

to therapies based on different technologies. Some of our competitors may develop and commercialize products that are introduced to market

earlier than our product candidates or on a more cost-effective basis. A number of our competitors have already commenced clinical testing

of product candidates and may be more advanced than we are in the process of developing such product candidates. If we are not first to

market or are unable to demonstrate superiority, on a cost-effective basis or otherwise, any products for which we are able to obtain

approval may not be successful.

We also face competition acquiring technologies complementary

to our INTASYL technology. Further, we may face competition with respect to product efficacy and safety, ease of use and adaptability

to modes of administration, acceptance by physicians, timing and scope of regulatory approvals, reimbursement coverage, price and patent

position, including dominant patent positions of others. If we are not able to successfully obtain regulatory approval or commercialize

our product candidates, we may not be able to establish market share and generate revenues from our technology.

If we fail to attract, hire and retain qualified

personnel, we may not be able to design, develop, market or sell our products or successfully manage our business.

We have a small core management team and are particularly

dependent on them. Accordingly, our business prospects are dependent on the principal members of our executive team, the loss of whose

services could make it difficult for us to manage our business successfully and achieve our business objectives. While we have entered

into an employment agreement with our Chief Executive Officer, he could leave at any time, in addition to our other employees, who are

all “at will” employees. Our ability to identify, attract, retain and integrate additional qualified key personnel is also

critical to our success. Competition for skilled research, product development, regulatory and technical personnel is intense, and we

may not be able to recruit and retain the personnel we need. The loss of the services of any key personnel, or our inability to hire new

personnel with the requisite skills, could restrict our ability to develop our product candidates.

We are subject to potential liabilities from

clinical testing and future product liability claims.

The use of our product candidates in clinical trials

and, if any of our product candidates receive regulatory approval, the sale of our product candidates for commercial use exposes us to

the risk of product liability claims. Product liability claims may be brought against us by patients, healthcare providers, consumers

or others who come into contact with our product candidates or approved products. We have, and will seek to obtain, clinical trial insurance

for current and any future clinical trials that we conduct, as well as liability insurance for any products that we market. However, there

is no assurance that we will be able to obtain insurance in the amounts we seek, or at all. We anticipate that licensees who develop our

products will carry liability insurance covering the clinical testing of our product candidates and the marketing of those product candidates,

if approved. There is no assurance, however, that any insurance maintained by us or our licensees will prove adequate in the event of

a claim against us. If we cannot successfully defend against product liability claims, we could incur substantial liabilities. Even if

claims asserted against us are unsuccessful, they may divert management’s attention from our operations and we may have to incur

substantial costs to defend such claims. Any of these outcomes could materially impact our business and financial condition.

We rely upon third parties for the manufacture

of the clinical supply for our product candidates.

We rely on third-party suppliers and manufacturers

to provide us with the materials and services to manufacture our product candidates for certain preclinical studies and for our clinical

trials, and we expect that we will continue to rely on third-party manufacturers for the supply of our product candidates in the future.

We have limited in-house manufacturing capabilities and resources, and we do not own or lease manufacturing facilities or have our own

supply source for the required materials to manufacture our compounds. Further, we have limited cGMP manufacturing capabilities and limited

experience scaling up of clinical supply as our internal capabilities are limited to small-scale production of research material. Accordingly,

we are dependent upon third-party suppliers and contract manufacturers to obtain supplies and manufacture our product candidates and we

will need to either develop, contract for, or otherwise arrange for the necessary manufacturers for these supplies.

There are a limited number of manufacturers that make

oligonucleotides and we currently contract with multiple manufacturers for the supply of our product candidates to reduce the risk of

supply interruption or availability. However, there is no assurance that our supply of our product candidates will not be limited, interrupted,

of satisfactory quality or be available at acceptable prices. For example, constraints on the supply chain and availability of resources

have resulted in delays and shortages at manufacturing facilities. While we have engaged with multiple manufacturers for the supply of

our product candidates in order to mitigate the impact of the loss or delay of any one manufacturer, there can be no assurance that our

efforts will be successful. If for any reason we are unable to obtain the clinical supply of our product candidates from our current manufacturers,

we would have to seek to contract with another major manufacturer. If we or any of these manufacturers are unable or unwilling to increase

its manufacturing capacity or if we are unable to establish alternative arrangements on a timely basis or on acceptable terms, the development

and commercialization of such an approved product may be delayed or there may be a shortage in supply. Any inability to manufacture our

product candidates or future approved drugs in sufficient quantities when needed would seriously harm our business.

Approval of any of our product candidates will not

occur unless the manufacturing facilities are in compliance with the FDA’s cGMP regulations in order to ensure that drug products

are safe and that they consistently meet applicable requirements and specifications. These requirements are enforced by the FDA through

periodic inspections of the manufacturing facilities and can result in enforcement action, such as warning letters, fines and suspension

of production if they are found not to be in compliance with the regulations. If our suppliers or manufacturers do not comply with the

FDA regulations for our product candidates, we may experience delays in timing or supply, be forced to manufacture our product candidates

ourselves or seek to contract with another supplier or manufacturer. If we are required to switch suppliers or manufacturers, we will

be required to verify that the new supplier or manufacturer maintains facilities and processes in line with cGMP regulations, which may

result in delays, additional expenses, and may have a material adverse effect on our ability to complete the development of our product

candidates.

Unstable market and economic conditions, including

elevated and sustained inflation, may have serious adverse consequences on our business, financial condition and stock price.

As has been widely reported, we are currently operating

in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by domestic and global monetary

and fiscal policy, geopolitical instability, ongoing military conflicts, and high domestic and global inflation. The U.S. Federal Reserve

and other central banks may be unable to contain inflation through more restrictive monetary policy and inflation may increase or continue

for a prolonged period of time. Inflationary factors, such as increases in the cost of clinical supplies, interest rates, overhead costs

and transportation costs may adversely affect our operating results. We continue to monitor these events and the potential impact on our

business. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date,

we may be adversely affected in the future due to domestic and global monetary and fiscal policy, supply chain constraints, consequences

associated with the coronavirus pandemic and the ongoing military conflicts, and such factors may lead to increases in the cost of manufacturing

our product candidates and delays in initiating studies. In addition, global credit and financial markets have experienced extreme volatility

and disruptions in the past several years and the foregoing factors have led to and may continue to cause diminished liquidity and credit

availability, declines in consumer confidence, declines in economic growth, uncertainty about economic stability and increased inflation.

There can be no assurance that deterioration in credit

and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by

any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity

and credit markets deteriorate, or do not improve, it may make any necessary debt or equity financings more difficult, more costly, and

more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect

on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In

addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive these difficult

economic times, which could directly affect our ability to attain our operating goals.

Our business and operations would suffer in the

event of computer system failures, cyberattacks or a deficiency in our cybersecurity.

Despite the implementation of security measures, our

internal computer systems and those of our third-party contractors and collaborators are vulnerable to damage from computer viruses, unauthorized

access, natural disasters, terrorism, war and telecommunication and electrical failures, cyberattacks or cyber-intrusions over the Internet,

attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security

breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber

terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world

have increased. Such an event could cause interruption of our operations. As part of our business, we and our third-party contractors

and collaborators maintain large amounts of confidential information, including non-public personal information on patients and our employees.

Breaches in security could result in the loss or misuse of this information, which could, in turn, result in potential regulatory actions

or litigation, including material claims for damages, interruption to our operations, damage to our reputation or otherwise have a material

adverse effect on our business, financial condition and operating results. We expect to have appropriate information security policies

and systems in place in order to prevent unauthorized use or disclosure of confidential information, including non-public personal information,

but there can be no assurance that such use or disclosure will not occur.

Risks Relating to Our Intellectual Property

We may be involved in litigation to protect our

patents and intellectual property rights and our ability to protect our patents and intellectual property rights is uncertain and may

subject us to potential liabilities.

We have filed patent applications, have pending patents

that we have licensed and those that we own and expect to continue to file patent applications. We may also need to license patents and

patent applications from research sponsored by us with third-parties. There is no assurance that these applications will result in any

issued patents or that those patents would withstand possible legal challenges or protect our technologies from competition. The patent

granting authorities have upheld stringent standards for the RNAi patents that have been prosecuted so far and, consequently, pending

patents that we have licensed and those that we own may continue to experience long and difficult prosecution challenges and may ultimately

issue with much narrower claims than those in the pending applications.

In addition, others may challenge the patents or patent

applications that we currently license or may license in the future or that we own and, as a result, these patents could be narrowed,

invalidated or rendered unenforceable, which would negatively affect our ability to exclude others from using the technologies described

in these patents. There is no assurance that these patents or other pending applications or issued patents we license or that we own will

withstand possible legal challenges. Moreover, the laws of some foreign countries may not protect our proprietary rights to the same extent

as do the laws of the United States. Our efforts to enforce and maintain our intellectual property rights may not be successful and may

result in substantial costs and diversion of management and key employees’ time. If we are unable to defend our licensed or owned

intellectual property, it may have a material and adverse impact on our business, results of operations and financial condition.

Third-parties may claim that we infringe their

patents, which may result in substantial liabilities and prevent us from pursuing the development of our product candidates.

Because the field we operate in is constantly changing

and patent applications are still being processed by government patent offices around the world, there is a great deal of uncertainty

about which patents will issue, when, to whom and with what claims. Although we are not aware of any blocking patents or other proprietary

rights, it is likely that there will be significant litigation and other proceedings, such as interference and opposition proceedings

in various patent offices, relating to patent rights in the field we operate. Further, many patents in the fields we are pursuing have

already been exclusively licensed to third-parties, including our competitors. It is possible that we may become a party to such proceedings.

If a claim should be brought against us and we are

found to infringe the rights of others, we may be required to pay substantial damages, be forced to stop the development of product candidates

affected by the claim, and/or establish licenses or similar arrangements. Furthermore, any such licenses may not be available when needed,

on commercially reasonable terms or at all. Whether an infringement claim is successful or not, the cost of these proceedings may be significant

and divert the attention of management and other key employees. As a result, we cannot be certain that our patents or those we license

will not be challenged by others, which could have a material adverse effect on our business, results of operations and financial condition.

We are dependent on the patents we own and the

technologies we license, and if we fail to maintain our patents or lose the right to license such technologies, our ability to develop

new products would be harmed.

Our success depends upon our ability to obtain and

maintain intellectual property protection for our product candidates. Any patents issued to us or our licensors may not provide us with

any competitive advantages, and there is no assurance that the patents of others will not have an adverse effect on our ability to do

business or to continue to develop our product candidates freely. Pending patents that we have licensed and those that we own may continue

to experience long and difficult prosecution challenges and may ultimately issue with much narrower claims than those in the pending applications.

Because of the extensive time required for development, testing, and regulatory review of a potential product, it is possible that, before

any of our product candidates can be commercialized, any related patent may expire or remain in force for only a short period following

commercialization, thus reducing any advantage provided by the patent. Further, even if our rights are valid, enforceable and broad in

scope, competitors may develop products based on technology that is not covered by our licenses or patents or patent applications that

we own. If we are unable to derive value from our licensed or owned intellectual property, it may have a material and adverse impact on

our business, results of operations and financial condition.

Third parties may hold or seek to obtain additional

patents that could make it more difficult or impossible for us to develop products based on our technologies without obtaining a license

to such patents, which licenses may not be available on attractive terms, or at all. If there is any dispute or issue of non-performance

between us and the respective licensing partner regarding the rights or obligations under the license agreements, the ability to develop

and commercialize the affected product candidate may be adversely affected. Moreover, if any of our existing licenses are terminated,

the development of the product candidates contemplated by the licenses could be delayed or terminated and we may not be able to negotiate

additional licenses on acceptable terms, if at all, which would have a material adverse effect on our business. To the extent that we

are required and are able to obtain multiple licenses from third parties to develop or commercialize a product candidate, the aggregate

licensing fees and milestones and royalty payments made to these parties may materially reduce our economic returns or even cause us to

abandon development or commercialization of a product candidate.

Risks Relating to Our Financial Condition

We will require substantial additional funds

to complete our research and development activities.

We have used substantial funds to develop our product

candidates and will need to raise additional substantial funds to continue our drug development efforts and support our operations. Our

future capital requirements and the period for which our existing resources are able to support our operations may vary significantly

from what we expect. We anticipate that we will need to raise substantial amounts of money to fund a variety of future activities integral

to the development of our business, which may include but is not limited to the following:

· To obtain regulatory approval for our product candidates;

· To manufacture products ourselves or through third parties;

· To acquire new technologies, licenses or products.

We are dependent on obtaining funding from third parties,

such as proceeds from the issuance of debt, sale of equity or strategic opportunities, in order to maintain our operations. We cannot

assure you that additional financing will be available to us on acceptable terms, or at all. If we cannot, or are limited in the ability

to, issue equity, incur debt or enter into strategic collaborations, we may be unable to fund the discovery and development of our product

candidates or improve our technology. If we fail to obtain additional funding when needed, we may ultimately be unable to continue to

develop and potentially commercialize our product candidates, and we may be forced to scale back or terminate our operations or seek to

merge with or be acquired by another company.

We have a history of

net losses, and we expect to continue to incur net losses for the foreseeable future and may not achieve or maintain profitability.

We have generated significant losses to date, have

not generated any product revenue and may not generate product revenue in the foreseeable future, or ever. We expect to incur significant

operating losses as we advance our product candidates through drug development and the regulatory process. Our ability to achieve profitability,

if ever, will depend on, among other things, us or our collaborators, obtaining regulatory approvals and successfully commercializing

our drug or biologic candidates. Even if we are able to successfully commercialize our drug or biologic candidates, we may not be able

to achieve or sustain profitability, which could have a material adverse effect on our business, financial condition and results of operations.

Future financing may be obtained through, and

future development efforts may be paid for by, the issuance of debt or equity, which may have an adverse effect on our stockholders or

may otherwise adversely affect our business.

If we raise funds through the issuance of debt or equity,

any debt securities or preferred stock issued will have rights, preferences and privileges senior to those of holders of our Common Stock

in the event of a liquidation. In such event, there is a possibility that once all senior claims are settled, there may be no assets remaining

to pay out to the holders of Common Stock. The terms of debt securities may also impose restrictions on our operations, which may include

limiting our ability to incur additional indebtedness, to pay dividends on or repurchase our capital stock, or to make certain acquisitions

or investments. In addition, we may be subject to covenants requiring us to satisfy certain financial tests and ratios, and our ability

to satisfy such covenants may be affected by events outside of our control. If we raise funds through the issuance of additional equity,

whether through private placements or public offerings, such an issuance would dilute current stockholders’ ownership in us, perhaps

substantially. The issuance of a significant amount of shares of Common Stock could cause the market price of our Common Stock to decline

or become highly volatile.

We expect to continue to incur significant research

and development expenses, which may make it difficult for us to attain profitability, and may lead to uncertainty as to our ability to

continue as a going concern.

We expend substantial funds to develop our technologies,

and additional substantial funds will be required for further research and development, including preclinical testing and clinical trials

of any product candidates, and to manufacture and market any products that are approved for commercial sale. Because the successful development

of our products is uncertain, we are unable to precisely estimate the actual funds we will require to develop and potentially commercialize

them. In addition, we may not be able to generate enough revenue, even if we are able to commercialize any of our product candidates,

to become profitable.

Changes in our operating plans, our existing and anticipated

working capital needs, the acceleration or modification of our expansion plans, increased expenses, potential acquisitions or other events

will all affect our ability to continue as a going concern. We have limited cash resources, have reported recurring losses from operations

since inception, negative operating cashflows and have not yet received product revenues. These factors raise substantial doubt regarding

our ability to continue as a going concern, and the Company’s current cash resources may not provide sufficient capital to fund

operations for at least the next 12 months from the date of the release of the consolidated financial statements included elsewhere in

this Annual Report. The continuation of the Company as a going concern depends upon our ability to raise additional capital through equity

offerings, debt offerings and/or strategic opportunities to fund our operations. There can be no assurance that we will be successful

in accomplishing these plans in order to continue as a going concern. Any such inability to continue as a going concern may result in

our common stockholders losing their entire investment. There is no guarantee that we will become profitable or secure additional financing.

Our ability to utilize

net operating loss carryforwards and other tax benefits may be limited.

We have historically incurred

net losses and may never achieve or sustain profitability. Under the Internal Revenue Code of 1986, as amended (the “Code”),

a corporation is generally allowed a deduction for net operating losses carried forward from a prior taxable year. Under that provision,

we can carry forward our net operating losses to offset our future taxable income, if any, until such net operating losses are used or

expire. Net operating losses incurred in tax years beginning after December 31, 2017, may be carried forward indefinitely, but are limited

to offsetting up to 80% of future taxable income. Certain net operating loss carryforwards predating December 31, 2017, could expire unused

before offsetting potential future income tax liabilities.

Additionally, an ownership

change, as defined by Section 382 and 383 of the Code, results from transactions increasing the ownership of certain stockholders or public

groups in the stock of a corporation by more than 50% over a three-year period. Pursuant to Section 382 and 383 of the code, if the Company

has experienced a change of control at any time since inception, utilization of the Company’s net operating loss or tax credit carryforwards

then in existence would be subject to an annual limitation. Any limitation may result in expiration of a portion of the net operating

loss or tax credit carryforwards before utilization.

We have completed multiple assessments of the available

net operating loss and tax credit carryforwards under Sections 382 and 383 of the Code through the year ended December 31, 2024 and determined

that we underwent multiple ownership changes during the period from inception to 2024. As a result, our net operating losses and tax credit

carryforwards are subject to substantial annual limitations under Sections 382 and 383 of the Code due to these ownership changes. The

Company has adjusted its net operating loss and tax credit carryforwards to address the impact of the ownership changes. We assess the

need to conduct an ownership change analysis to determine whether any changes occurred in ownership that would limit net operating loss

or tax credit carryforwards on an annual basis. We may experience ownership changes in the future as a result of subsequent shifts in

our stock ownership, some of which may be outside of our control. If an ownership change occurs and our ability to use our net operating

loss and tax credit carryforwards is materially limited, it could harm our future operating results by effectively increasing our future

tax obligations.

Risks Relating to Our Securities

The price of our Common Stock has been and may

continue to be volatile.

Our stock price has historically fluctuated widely

and is likely to continue to be volatile. Because we are at an early stage of development and in the absence of product revenue as a measure

of operating performance, we anticipate that the market price for our Common Stock may be influenced by, but not limited to, such factors

as:

· Regulatory or legal developments in the United States;

· The recruitment or departure of key personnel;

· To acquire new technologies, licenses or products; and

· General economic, industry and market conditions.

The stock market, in general, and the markets for drug

delivery and pharmaceutical company stocks, in particular, have experienced extreme volatility, that has often been unrelated to the operating

performance of these particular companies. These broad market fluctuations may adversely affect the trading price of our Common Stock

and could result in the loss of all or part of your investment. In addition, the limited trading volume of our stock may contribute to

its volatility. Moreover, if we are unable to trade above $1.00 for a certain period of time, or fulfill the other continued listing standards,

The Nasdaq Stock Market (“Nasdaq”) may delist our Common Stock. Delisting our Common Stock from Nasdaq would adversely

affect our trading volume and would likely negatively impact our trading price.

We may not be able to maintain compliance with

the continued listing requirements of The Nasdaq Capital Market.

To maintain continued listing on The Nasdaq Capital

Market, we must satisfy minimum financial and other requirements. For example, Nasdaq Listing Rule 5550(b)(1) requires companies listed

on the Nasdaq Capital Market to maintain stockholders’ equity of at least $2.5 million for continued listing. As of December 31,

2024, our stockholders’ equity was $4.7 million and there can be no assurance that we will be able to maintain or increase our stockholders’

equity in the future. If our stockholders’ equity falls below $2.5 million, as a result of operating losses or for other reasons,

or if we are unable to demonstrate to Nasdaq’s satisfaction that we subsequently regained compliance with this requirement, Nasdaq

will notify us of such non-compliance. If we receive such notice from Nasdaq, in accordance with the Nasdaq Listing Rules, we will have

45 calendar days from the date of the notification to submit a plan to regain compliance with Nasdaq Listing Rule 5550(b)(1). If our compliance

plan is accepted, we may be granted up to 180 calendar days from the date of the initial notification to evidence compliance. If our compliance

plan is not accepted or we are otherwise unable to evidence compliance within Nasdaq’s allotted timeframe, Nasdaq may take steps

to delist our Common Stock.

In addition, Nasdaq Listing Rule 5550(a)(2) requires

a minimum bid price of at least $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid

price requirement exists if the deficiency continues for a period of 30 consecutive business days. Although the Company is currently in

compliance with this requirement, there can be no assurance that we will be able to maintain compliance. We have in the past effected

reverse stock splits of our Common Stock in order to regain or maintain compliance with this requirement (most recently on July 5, 2024).

Nasdaq Listing Rule 5810(c)(3)(A)(iv) states that any listed company that fails to meet this requirement and has effected a reverse stock

split over the prior one-year period, or has effected one or more reverse stock splits over the prior two-year period with a cumulative

ratio of 250 shares or more to one, may not be eligible for an automatic 180-day grace compliance period and the Nasdaq Listing Qualifications

Department is obligated to immediately issue a delisting determination. Therefore, if we were to fall out of compliance with the minimum

bid price requirement prior to July 5, 2025, we would not be able to effect a reverse stock split and would immediately be issued a delisting

determination.

Such a delisting would have an adverse effect on the

market liquidity of our securities, decrease the market price of our securities, result in the potential loss of confidence by investors,

suppliers, customers and employees and fewer business development opportunities, and adversely affect our ability to obtain financing

for the continuation of our operations.

Our Board of Directors has the authority to issue

shares of “blank check” preferred stock and the terms of the preferred stock may reduce the value of our Common Stock.

We are authorized to issue up to 10,000,000 shares

of preferred stock in one or more series. Our Board of Directors (the “Board”) may determine the terms of future preferred

stock offerings without further action by our stockholders. The issuance of our preferred stock could affect the rights of existing stockholders

or reduce the value of our outstanding preferred stock or Common Stock. In particular, rights granted to holders of certain series of

preferred stock may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights and restrictions

on our ability to merge with or sell our assets to a third party.

We may acquire other businesses or form joint

ventures that may be unsuccessful and could dilute your ownership interest in the Company.

As part of our business strategy, we may pursue future

acquisitions of other complementary businesses and technology licensing arrangements. We also may pursue strategic alliances. We have

limited experience with respect to acquiring other companies and with respect to the formation of collaborations, strategic alliances

and joint ventures. We may not be able to integrate such acquisitions successfully into our existing business, and we could assume unknown

or contingent liabilities. We also could experience adverse effects on our reported results of operations from acquisition related charges,

amortization of acquired technology and other intangibles and impairment charges relating to write-offs of goodwill and other intangible

assets from time to time following the acquisition. Integration of an acquired company requires management resources that otherwise would

be available for ongoing development of our existing business. We may not realize the anticipated benefits of any acquisition, technology

license or strategic alliance. There is no assurance that we will be successful in developing such assets, and a failure to successfully

develop such assets could diminish our prospects.

To finance future acquisitions, we may choose to issue

shares of our Common Stock or preferred stock as consideration, which would dilute current stockholders’ ownership interest in us.

Alternatively, it may be necessary for us to raise additional funds through public or private financings. Additional funds may not be

available on terms that are favorable to us and, in the case of equity financings, may result in dilution to our stockholders. Any future

acquisitions by us also could result in large and immediate write-offs, the incurrence of contingent liabilities or amortization of expenses

related to acquired intangible assets, any of which could harm our operating results.

Provisions of our certificate of incorporation

and bylaws and Delaware law might discourage, delay or prevent a change of control of the Company or changes in our management and, as

a result, depress the trading price of our Common Stock.

Our certificate of incorporation and bylaws contain

provisions that could discourage, delay or prevent a change of control of the Company or changes in our management that the stockholders

of the Company may deem advantageous. These provisions:

Although we believe these provisions collectively provide

for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our Board, they would apply even if the offer

may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders

to replace or remove our current management team by making it more difficult for stockholders to replace members of our Board, which is

responsible for appointing the members of our management.

Moreover, because we are incorporated in Delaware,

we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess

of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction

in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed

manner.

ITEM 1B. UNRESOLVED STAFF COMMENTS

None.

ITEM 1C. CYBERSECURITY

Risk management and strategy

We are increasingly dependent on sophisticated software

applications and computing infrastructure to conduct key operations. We depend on both our own systems, networks, and technology as well

as the systems, networks and technology of our contractors, consultants, vendors and other business partners.

Cybersecurity Program

Given the importance of cybersecurity to our business,

we maintain a robust cybersecurity program to support both the effectiveness of our systems and our preparedness for information security

risks. This program includes a number of safeguards, such as: continuous monitoring for internal and external threats; regular evaluations

of our cybersecurity program, including periodic external reviews; and industry benchmarking. We are implementing cybersecurity awareness

trainings for all employees. Our program leverages standard industry frameworks to strengthen our program effectiveness and reduce cybersecurity

risks.

We use a risk-based approach with respect to our use

and oversight of third-party service providers, tailoring processes according to the nature and sensitivity of the data accessed, processed,

or stored by such third-party service provider. We use a number of means to assess and manage cyber risks related to our third-party service

providers, including conducting due diligence in connection with onboarding new vendors and seeking to include appropriate security terms

in our contracts where applicable.

Process for Assessing, Identifying and Managing Material Risks from

Cybersecurity Threats

In the event of a cybersecurity incident, designated

personnel are responsible for assessing the severity of an incident and associated threat, containing the threat, remediating the threat,

including recovery of data and access to systems, analyzing any reporting obligations associated with the incident, and performing post-incident

analysis and program enhancements. We maintain a disaster recovery plan in the event of a significant cybersecurity incident.

We have relationships with a number of third-party

service providers to assist with cybersecurity containment and remediation efforts, including insurance providers and various law firms.

Governance

Management Oversight

The

controls and processes employed to assess, identify and manage material risks from cybersecurity threats are implemented and

overseen by the use of consultants as the Company does not have a full-time dedicated cybersecurity position in the Company.Our consultants

have over 20 years of experience in information technology matters and are responsible

for the day-to-day management of the cybersecurity program, including the prevention, detection, investigation, response to, and

recovery from cybersecurity threats and incidents, and are regularly engaged to help ensure the cybersecurity program functions

effectively in the face of evolving cybersecurity threats.

Board Oversight

The Board of Directors (the “Board”)

has overall responsibility for risk oversight and cybersecurity risk matters.The Board is responsible for discussing with management

the Company’s data privacy, information technology and security and cybersecurity risk exposures, including: (i) the potential impact

of those exposures on the Company’s business, financial results, operations and reputation; (ii) the programs implemented by management

to monitor and mitigate any exposures; and (iii) major legislative and regulatory developments that could materially impact the Company’s

data privacy and cybersecurity risk exposure.

Cybersecurity Risks

Our cybersecurity risk management processes are integrated

into our overall information technology (“IT”) processes. As part of our IT process, we identify, assess and evaluate

risks impacting our operations across the Company, including those risks related to cybersecurity. We also maintain cybersecurity insurance

providing coverage for certain costs related to cybersecurity-related incidents that impact our own systems, networks, and technology

or the systems, networks and technology of our contractors, consultants, vendors and other business partners.

As of December 31, 2024, we are not aware of any material

risks from cybersecurity threats, including as a result of any previous cybersecurity incidents, that have materially affected the business

strategy, results of operations or financial condition of the Company or are reasonably likely to have such a material effect. While we

maintain a robust cybersecurity program, the techniques used to infiltrate information technology systems continue to evolve. Accordingly,

we may not be able to timely detect threats or anticipate and implement adequate security measures. For additional information, see “Item

1A—Risk Factors.”

ITEM 2. PROPERTIES

The Company’s lease for

its corporate headquarters and primary research facility in Marlborough, Massachusetts expired on March 31, 2024. The Company has continued

operations as a primarily remote business with a rented lab space and has contracted a private mailbox with an address of 11 Apex Drive,

Suite 300A, PMB 2006, Marlborough, MA 01752, to use as its principal mailing address for SEC and other purposes.

The Company has also contracted

with LifeSciences PA located at 411 Swedeland Road, King of Prussia, PA 19406 for access to full working space for normal hours of operations

at a fee for $300 per month, cancellable at any time.

The Company entered into a lease

for a laboratory facility located at 17 Briden Street, Worcester, Massachusetts. The lease had an original expiration date of August 31,

2024, and was subsequently extended through February 28, 2025. The Company continues to lease the space on a month-to-month basis.

Monthly rent is approximately $2,500.

ITEM 3. LEGAL PROCEEDINGS

From time to time, the Company may become a party to

various legal proceedings and complaints arising in the ordinary course of business. To our knowledge, we are not currently a party to

any actual or threatened material legal proceedings.

ITEM 4. MINE SAFETY DISCLOSURES

Not applicable.

PART II

Market Information

Our Common Stock is listed on The Nasdaq Capital Market

under the symbol “PHIO.”

Holders

At March 20, 2025, there were approximately 14 holders

of record of our Common Stock. Because many of our shares are held by brokers and other institutions on behalf of stockholders, we are

unable to estimate the total number of individual stockholders represented by these holders of record.

Dividends

We have never paid any cash dividends and do not anticipate

paying any cash dividends on our Common Stock in the foreseeable future.

Recent Sales of Unregistered Sales of Securities

No sales or issuances of unregistered securities occurred

that have not previously been disclosed in a Quarterly Report on Form 10-Q or in a Current Report on Form 8-K for the year ended December

31, 2024.

Purchases of Equity Securities by the Issuer and Affiliated Purchases

We did not repurchase any shares of our Common Stock

during the years ended December 31, 2024 or 2023.

ITEM 6. RESERVED

The following discussion of our financial condition

and results of operations should be read in conjunction with our consolidated financial statements and the notes to those consolidated

financial statements included in Item 8 of this Annual Report on Form 10-K. This discussion contains forward-looking statements that

involve significant risks and uncertainties. As a result of many factors, such as those set forth under “Risk Factors” and

elsewhere in this Annual Report on Form 10-K, our actual results may differ materially from those anticipated in these forward-looking

statements. Please refer to the discussion under the heading “Forward-Looking Statements” above.

Overview

Phio Pharmaceuticals Corp. (“Phio,”

“we,” “our” or the “Company”) is a clinical stage biotechnology company whose

proprietary INTASYLTM self-delivering RNAi® small interfering RNA gene silencing technology is designed to make immune cells

more effective in killing tumor cells. We are developing therapeutics that are designed to leverage INTASYL to precisely target specific

proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems.

We are committed to discovering and developing innovative cancer treatments for patients by creating new pathways toward a cancer-free

future.

PH-762 is an INTASYL compound designed to reduce the

expression of cell death protein 1 (“PD-1”). PH-762 is currently being evaluated in a U.S. multi-center Phase 1b dose-escalating

clinical trial through the intratumoral injection of PH-762 for the treatment of patients with cutaneous squamous cell carcinoma, melanoma

and Merkel cell carcinoma. The trial (NCT 06014086) is designed to evaluate the safety and tolerability of neoadjuvant use of intratumorally

Source: SEC EDGAR (public domain) · 10-K for the period ended 2024-12-31, filed 2025-03-31 · accession 0001683168-25-002134

Filing HTML rendered to line-structured narrative text by the shipped reducer (datafeeds.edgar_fulltext.visible_text, keep_table_headers=True): scripts and inline-XBRL headers are dropped, and table content is reduced to its short label cells — numeric table data is not rendered and is therefore not counted. The same rendering is used for every year, so a year-over-year comparison is like for like.

The text is our rendering of the filing, not a facsimile: original pagination, typography and tables are not reproduced, and the numbers live in the financial statements (FA).

The outline locates item HEADINGS in this document. Only Items 1A and 7 have certified boundaries elsewhere in the terminal (the redline and the narrative-overlap number); every span here runs from one heading found to the next heading found.

How the outline was chosen. It is the longest chain of item headings that runs forward through both the document and the standard item order: 18 headings are on that chain and 17 further heading-shaped lines are not — the table-of-contents echo of every item, cross-references and exhibit-list mentions. Each entry's length is measured from its heading to the next heading on the chain.